MyOme - Employers

Demand for Genomic Benefits is Growing. Value Should Too.

Genomic health benefits are quickly becoming a fixture in competitive benefits packages. But most tests being offered — including those deployed at Fortune 500 companies — sequence less than 2% of the genome, cover only one disease area, or come without clinical support^1-3. MyOme sequences the whole-genome, surfaces risk across diseases and medication response, and includes board-certified genetic counseling with every result.

1. Cohn B, et al. Molecular Genetics & Genomic Medicine (2023). 2. Society for Human Resource Management. 2018 Employee Benefits: The Evolution of Benefits. SHRM (2018). 3. McDonald WS, et al. Molecular Genetics & Genomic Medicine (2020).

Schedule a Call

MyOme Benefits Package

Hereditary Disease Risk

40+ conditions

Medication Response

70+ medications

Complex Disease Risk

Coronary Artery Type 2 Diabetes Breast Cancer Prostate Cancer

Genetic Counseling

Board-certified consultations

How Many of Your Employees Are Carrying Preventable Health Risks?

MyOme Proactive Health tests identify disease risks before symptoms appear, catching what routine checkups miss, and predict how employees will respond to medications, speeding the journey to the right treatment.

Together, these insights personalize preventive care, reduce adverse drug reactions, and lower healthcare costs before they compound.

Genomic risk chart data
Coronary artery disease	Approximately 50 percent of risk is attributable to genetic factors.
Breast cancer	Approximately 50 percent of risk is attributable to genetic factors.
Prostate cancer	Approximately 70 percent of risk is attributable to genetic factors.
Type 2 diabetes	Approximately 70 percent of risk is attributable to genetic factors.
Medication response findings	Approximately 95 percent of employees have genetic factors that may impact medication responses.

Uncover Hidden Disease Risk Missed by Routine Checkups

Percent of risk attributable to genetic factors

Coronary artery disease

~50%

Breast cancer

~50%

Prostate cancer

~70%

Type 2 diabetes

~70%

Help Employees Find the Right Medication Sooner

95%

of employees have genetic factors that may impact medication responses

1. CAD Risk: McPherson R, et al. Circulation Research (2016). 2. Breast Cancer Risk: Sokolova, et al. Histopathology (2022). 3. Prostate Cancer Risk: NCI. Genetics of Prostate Cancer. Web. 4. T2D Risk: Bonnefond A, et al. Lancet Diabetes Endocrinol (2025). 5. PGx Likelihood: (a) Van Driest SL, et al. Clin Pharmacol Ther (2014). (b) Bush WS, et al. Clin Pharmacol Ther(2016). (c) Ji Y, et al. J Mol Diagn (2016).

Employee Participation

44%

of employees engaged in the program within 90-days of access to MyOme testing

Disease Risk Detection

~14%

of employees tested carried at least one clinically significant, high-impact risk variant linked to a health condition

High-Risk Classification

~20%

of employees were identified as high-risk for cardiometabolic disease or cancer

*Results averaged across active employer programs.

More than 50% of cancers and up to 80% of cardiac diseases are preventable. By integrating genomics into employer health programs, we provide participants with knowledge that can save lives and significantly improve outcomes.

How Genomic Risk Insights Shape Care to Reduce Healthcare Spend

Avoid
Hospitalizations

Medication Response insights enable safe prescribing from the start. This type of screening is proven to reduce medication-related ER visits and inpatient stays by ~40%.¹

~40%

Reduce Cancer Treatment Costs

Single-Gene Risk insights for cancers, including breast cancer, can stimulate early screening, detection, and treatment. Treating breast cancer early can reduce treatment costs by >$500K.²

>$500K

Cut Heart Disease Spend

Polygenic Risk Scores for Coronary Artery Disease (CAD) can lead to early interventions—like statin therapy—that reduce heart event risk and avoid $40K in annual treatment costs.³

~$40K

Fragala MS, Keogh M, Goldberg SE, Lorenz RA, and Shaman JA. The Pharmacogenomics Journal. 2 Oct 2024; 24(5):30. doi: 10.1038/s41397-024-00350-1.
Reddy SR, Chung KC, Kansal AR, et al. Current Medical Research and Opinion. 2022; 38(5):791-800. doi: 10.1080/03007995.2022.2047536.
Kazi DS, Elkind MSV, Deutsch A, et al. Circulation. 23 Jul 2024; 150(4):e89-e101. doi: 10.1161/CIR.0000000000001258.

Employee support and privacy

Every employee receives their results privately, with access to a certified genetic counselor to help them understand findings and plan next steps. Your organization sees only aggregate, de-identified program data — never individual results. All genomic data is encrypted, HIPAA-compliant, and never shared without the employee's explicit consent.

Privacy and Security

Get in touch to find the right program

We want to help you find the right program for your organization and employees. Reach out to learn more about how MyOme can elevate your health benefit offerings with precision risk insights.

Schedule a Call